Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ad26 Mos4 HIV (Primary) ; HIV clade C gp140 vaccine (Primary) ; HIV mosaic gp140 vaccine (Primary) ; Aluminium phosphate
Indications HIV-1 infections
Focus Registrational; Therapeutic Use
Acronyms MOSAICO
Sponsors Janssen Vaccines and Prevention B.V

13 Sep 2023 Status changed from discontinued to completed.
15 Aug 2023 Planned End Date changed from 30 Aug 2023 to 25 Aug 2023.
15 Aug 2023 Planned primary completion date changed from 16 Aug 2023 to 25 Aug 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com